Cannabis Compound MELTS Liver Fat

A man carefully harvesting cannabis plants in a greenhouse

Two non-intoxicating cannabis compounds just demonstrated the ability to remodel liver metabolism and slash fat accumulation in diseased livers through a mechanism scientists had never connected to cannabinoids before.

Story Snapshot

CBD and CBG reduced liver fat and improved glucose control in preclinical models of fatty liver disease by boosting emergency energy reserves and reactivating cellular cleanup systems
CBG outperformed CBD, delivering stronger reductions in body fat, insulin resistance, and harmful cholesterol
The study identified phosphocreatine energy buffering and lysosomal restoration as dual therapeutic targets, a novel mechanism for cannabinoid action in metabolic disease
Findings remain preclinical with no human trial data yet, but position CBD and CBG as experimental drug candidates for MASLD, the world’s most common chronic liver condition

The Discovery That Shifts the Cannabinoid Conversation

Prof. Joseph Tam’s team at Hebrew University of Jerusalem published findings in the British Journal of Pharmacology that cannabidiol and cannabigerol ameliorate metabolic dysfunction-associated steatotic liver disease through pathways the field had overlooked. The compounds increased hepatic phosphocreatine, an emergency energy buffer that prevents ATP depletion in stressed liver cells, while simultaneously reactivating lysosomal cathepsins that clear harmful lipids and cellular waste. This dual metabolic remodeling reduced triglycerides, ceramides, and overall liver fat while improving systemic glucose handling in animal models fed high-fat diets. The work frames these plant molecules not as wellness supplements but as pharmaceutical leads targeting a disease affecting millions worldwide.

CBG Emerges as the Stronger Contender

Head-to-head comparisons revealed cannabigerol delivered more robust metabolic improvements than its better-known cousin. CBG-treated models showed greater reductions in body fat mass, sharper improvements in insulin sensitivity, and stronger decreases in total and LDL cholesterol compared to CBD. Both compounds are non-intoxicating, avoiding the psychoactive and regulatory complications of THC, yet CBG remains a minor cannabinoid with sparse human safety data. The findings elevate CBG from cannabis chemistry footnote to potential therapeutic priority, though the gap between preclinical promise and clinical proof remains wide and littered with the wreckage of failed metabolic-disease drugs.

The Liver Disease No One Can Ignore

MASLD, formerly known as NAFLD, stands as the most common chronic liver disease globally, driven by obesity, type 2 diabetes, and metabolic syndrome. Excess fat accumulation in liver cells can progress to inflammation, fibrosis, cirrhosis, and liver cancer. Approved pharmacologic treatments remain scarce, leaving lifestyle modification as the primary intervention, a strategy patients struggle to sustain long-term. The endocannabinoid system modulates liver lipid metabolism and insulin sensitivity, and earlier research showed CB1 receptor antagonists could reduce steatosis, though psychiatric side effects derailed that approach. Non-psychoactive cannabinoids like CBD and CBG offer a subtler modulation without strong CB1 activation, threading a therapeutic needle between efficacy and tolerability.

Energy Buffering and Cellular Recycling as Drug Targets

The study’s mechanistic novelty lies in identifying phosphocreatine buffering and lysosomal function as cannabinoid-responsive pathways in fatty liver. Phosphocreatine serves as a rapid-access energy reserve, cushioning hepatocytes against ATP shortfalls that drive lipid accumulation and metabolic dysfunction. Lysosomal cathepsins act as cellular recycling enzymes, breaking down waste and clearing harmful lipids. CBD and CBG restored both systems in diseased liver models, a dual-target approach that addresses inefficient energy handling and impaired lipid clearance simultaneously. Independent research has flagged autophagy and lysosomal dysfunction as contributors to MASLD progression, making this cannabinoid connection particularly timely as the field hunts for fresh therapeutic angles after repeated clinical trial failures.

The Translation Gap and Regulatory Reality

These findings carry zero weight for clinical practice today. No human trials testing pharmaceutical-grade CBD or CBG specifically for MASLD with rigorous dosing, safety monitoring, and metabolic endpoints have been reported. High-dose CBD can elevate liver enzymes and interact with medications metabolized by the same pathways, a concern amplified in MASLD populations already taking multiple drugs for diabetes, hypertension, and cholesterol. The study’s authors stress the work is experimental, yet the CBD and CBG product industry will predictably deploy this research in marketing narratives long before regulators validate therapeutic claims.

The pathway from bench science to bedside therapy runs through phase trials, regulatory scrutiny, formulation challenges, and real-world safety validation. Pharmaceutical and biotech firms may pursue intellectual property around standardized cannabinoid formulations or liver-targeting delivery systems, potentially transforming experimental findings into regulated drugs. Alternatively, the commercial cannabinoid ecosystem could outpace science, flooding the market with unproven products that claim liver benefits without the evidence base to support them. That tension between academic rigor and entrepreneurial opportunism will define how this story unfolds, determining whether CBD and CBG become legitimate MASLD therapies or simply the latest overhyped supplements cashing in on preclinical promise.